Fresh analysis reveals that patients who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain lost weight much more quickly than those who halt conventional lifestyle regimens.
Published data in a prominent health publication demonstrates that while obese individuals often shed about a fifth of their total mass while using the jabs, the mass is regained at an estimated rate of nearly a kilo each month upon discontinuation.
"Individuals using these drugs should be aware of the potential of quick weight regain when the medication is stopped," cautioned lead investigator Dr. Susan Jebb.
Such speed of recovery means a return to starting mass in about a year and a half.
Weighing Approaches
The study, which examined dozens of trials involving over 9,000 of patients, compared the results of GLP-1 agonists with other pills.
The team emphasize that individuals who lose weight through diet and exercise generally have a slower creep back—around 0.1 kg a month—once they finish.
Explaining the Quick Regain
Experts suggest the mechanism of the jabs is key to understanding the amplified regain.
GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.
"Artificially providing GLP-1 levels several times higher than normal could lead to the system to generate a reduced amount of its endogenous hormone, and could reduce responsiveness to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Stopping of this medication means appetite is unsuppressed, making excessive eating far more likely."
A Chronic Disease?
The NHS recommend the injections for individuals with weight-linked health risks, alongside recommended diet and exercise modifications.
Many experts argue that, considering the high risk of weight regain, the therapy might need to be long-term.
This view is reinforced by drug manufacturers, who say that the results "highlight the persistent character of obesity," akin to managing conditions like diabetes.
User Accounts
People who have stopped the medication describe a sudden return of cravings.
"It was like something flipping and I was suddenly ravenous," described an individual.
The struggle is exacerbated if users have not adopted permanent dietary or behavioural modifications during treatment.
Widespread Adoption
Survey data show that millions of people in the UK have used weight-loss jabs in the past year, with interest remaining high.
- Adoption is more common among females than men.
- The 40s and 50s demographic shows the highest level of interest.
- Many access the medications through private prescriptions rather than public health services.
In conclusion, researchers emphasize that while the jabs are potent agents for weight loss, they are not a magic fix and maintained weight loss hinges on integrated lifestyle changes.
